Please login to the form below
biologic
This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.
Novartis cuts manufacturing jobs in Switzerland and UK
This reflects the move away from simpler small molecule-based pills towards a greater reliance on biologics and the new and highly complex manufacturing required for cell therapies, such as
Latest news
-
London cancer hub launched by Cancer Research UK
The first research programme is aimed at discovering and developing new biologic cancer drugs, with an emphasis on the tumour microenvironment (TME) – i.e. ... Programme two will use imaging techniques to see how biologic treatments, such as cell
-
Gilead and Galapagos JAK contender scores in RA trial
drugs to help patients with active RA who don’t respond adequately to current biologics.
-
New data keeps AbbVie’s star pipeline therapies on track
For risankizumab, the new data could be important to help AbbVie differentiate its IL-23 inhibitor from a clutch of new biologic therapies for psoriasis from Novartis, Eli Lilly and Johnson
-
BMS psoriasis drug hits the mark in phase II
competitive with many biologic therapies approved in the setting, ”according to analyst Matt Phipps of William Blair. ... greater improvement (PASI 75) at week 12 in 75% of patients overall, and 81% of those previously treated with a biologic drug.
-
Boehringer bolts on another immuno-oncology company
Immunotherapeutics and earlier alliances with Siamab, AbeXXa Biologics, CureVac and Philogen.
More from news
Approximately 20 fully matching, plus 581 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
targeting drugs from the likes of Crescendo Biologics and Pfizer, and Celldex’CD27-targeting antibody varlilumab which is in phase II testing for various solid tumour types. ... Meanwhile, AbbVie and Johnson &Johnson have both struck deals this year
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
In recent years, biosimilars (highly similar copies of biologic medicines) have taken large shares of many markets.
-
Mylan sees the UK paving the way for an insulin game changer
4th generation of biologics.
-
‘How is your day?’
Plasma protein therapies are biologic medicines – derived from human plasma or recombinant analogues (that treat bleeding disorders) – that treat a range of life-threatening, chronic and genetic diseases.
-
Leo has its eyes on the prize
Advancing biologics and adding biomarkers for precision medicine is one of the steps we are going to see in the coming years. ... We have multiple approaches such as combining biologics where we may be able to address the inflamation and itch while
More from intelligence
Approximately 2 fully matching, plus 67 partially matching documents found.
Latest appointments
-
BMS appoints CCO, Stephen Davies joins Eisai and more
Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Nabriva Therapeutics appoints chief medical officer
medical affairs for small molecules and biologics.
-
Ipsen appoints Aidan Murphy as EVP, technical operations
Ipsen appoints Aidan Murphy as EVP, technical operations. He is promoted from senior VP biologics development and manufacturing. ... being senior vice president biologics development and manufacturing.
-
Andy Busch joins Shire as its CSO and head of research and development
both biologics and small molecules.”.
More from appointments
Approximately 7 fully matching, plus 45 partially matching documents found.
Latest from PMHub
-
It’s all about patient outcomes… right?
a novel biologic agent. ... Consequently, the roll-out of the novel biologic agent was conducted in a manner that was sensitive to the PCP/specialist interaction observed, ensured smooth communications and optimised patient outcomes.
-
Biotech: it's a people business
Biologic therapies have become a central part of modern day medicine and a key part of biotech and pharma portfolios.
-
Webcast: Biosimilars: Friend or Foe to Healthcare?
Webcast: Biosimilars: Friend or Foe to Healthcare? Understanding the opportunities for biosimilars and the threats to innovator biologics. ... Gain greater insight into what companies entering the market need to do to effectively launch their follow-on
-
Infographic: RA Perceptions
Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market ... Biosimilars (the approved follow-on
-
Biosimilars: Getting the flock to market
originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost. ... So biosimilars not only increase patient access to tried and trusted biologics, they may accelerate adoption of new agents.
More from PMHub
Approximately 7 fully matching, plus 41 partially matching documents found.
Featured jobs
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Associate Scientific Director
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Healthcare PR Senior Account Manager
-
Salary TBC
-
Account Director - Digital
-
Great salary and benefits
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Systematic Review Lead- London
-
Negotiable
-
Senior Medical Writer
-
Salary is DOE
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
Subscribe to our email news alerts
- Bluebird’s first gene therapy gets European fast track
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- Moving annual total (MAT)
- J&J files ‘breakthrough’ bladder cancer drug in US
- After Lucentis setback, Novartis trumpets data on follow-up drug
- AstraZeneca chief on Brexit: “It’s going to be really painful”
- Roche’s Tecentriq misses survival mark in frontline NSCLC
- Amarin hits jackpot with astonishing heart benefits from fish oil product
- Novartis cuts manufacturing jobs in Switzerland and UK
- New Awards scheme for medical and scientific professionals
- Random42 Exhibiting at BioCap Conference 2018
PMHub
mXm Medical Communications
mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...
Latest intelligence
- Solaris Health looks at the gene therapy revolution
- Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
Quick links
Infographics
